Adrenal Apoplexy - University of Colorado Denver

More documents

Recommendations

Info

Adrenocortical Carcinoma Biochemical Evaluation • Detailed hormone evaluation • Steroid precursors – DHEA-S • Identify tumor marker
Incidentaloma:Metastatic Disease • 2.1-2.5% prevalence of metastatic disease among incidentalomas • Occult malignancy: adrenal mass at presentation 5.8% • FNAB: only in patients with history of cancers (particularly lung, breast, kidney), – no signs of other metastases, – a heterogeneous mass with a high unenhanced attenuation value (>20HU) – after exclusion of pheochromocytoma. • PET CTS Schteingart et al Endocrine Related Cancer 2005; Barzon et al Eur J Endocrinol 2003; Lee et al Surgery 1998
Page 1 and 2: Department of Surgery Grand Rounds
Page 3 and 4: Case History 1: • A 55 year old m
Page 5 and 6: Question 1: The next step in manage
Page 7 and 8: Adrenal Incidentaloma 3 questions
Page 9 and 10: Case History 4 • 51 year old fema
Page 11 and 12: Question 4: Which of the following
Page 13 and 14: Adrenal Incidentaloma Screening •
Page 15 and 16: Adrenal Incidentaloma Follow up •
Page 17 and 18: Cushing’s Syndrome • Exogenous
Page 19 and 20: Case History 3 • 44 year old fema
Page 21 and 22: Question 3: You advise which manage
Page 23 and 24: Pheochromocytoma Intra-operative Ma
Page 25 and 26: Risk Factors for Hemodynamic Instab
Page 27 and 28: Pheochromocytoma Postoperative Mana
Page 29 and 30: Primary Hyperaldosteronism Screenin
Page 31 and 32: Primary Hyperaldosteronism Adrenal
Page 33 and 34: Hyperaldosteronism Surgical Therapy
Page 35 and 36: Question 2: The next best course of
Page 37 and 38: Adrenocortical Carcinoma • Determ
Page 39: Adrenocortical Carcinoma Imaging
Page 43 and 44:
Adrenocortical Carcinoma Medical Th
show all

Adrenal Apoplexy - University of Colorado Denver

Create successful ePaper yourself

Delete template?

Save as template?